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Abstract
Background: Cytoplasmic stress granules (SGs) are specialized storage sites of untranslated mRNAs whose formation 
occurs under different stress conditions and is often associated with cell survival. SGs-inducing stresses include 
radiations, hypoxia, viral infections, and chemical inhibitors of specific translation initiation factors. The FDA-approved 
drug bortezomib (Velcade®) is a peptide boronate inhibitor of the 26S proteasome that is very efficient for the 
treatment of myelomas and other hematological tumors. Solid tumors are largely refractory to bortezomib. In the 
present study, we investigated the formation of SGs following bortezomib treatment.
Results: We show that bortezomib efficiently induces the formation of SGs in cancer cells. This process involves the 
phosphorylation of translation initiation factor eIF2α by heme-regulated inhibitor kinase (HRI). Depletion of HRI 
prevents bortezomib-induced formation of SGs and promotes apoptosis.
Conclusions: This is the first study describing the formation of SGs by a chemotherapeutic compound. We speculate 
that the activation of HRI and the formation of SGs might constitute a mechanism by which cancer cells resist 
bortezomib-mediated apoptosis.
Background
The proteasome is a large multi-subunit complex respon-
sible for the degradation of various proteins, including
cell cycle regulators and apoptotic factors, by ubiquitin-
dependent and -independent mechanisms [1,2]. Protea-
some inhibitors are known to induce apoptosis in prolif-
erating cells [3-6]. The proteasome inhibitor bortezomib
is now FDA-approved and in clinical use against mantle
cell myeloma and multiple myeloma, against which it dis-
plays strong anti-tumor activity [7-14]. However, solid
tumors of various histological origins are refractory to
bortezomib treatment, and this resistance is also
observed in cancer cell lines derived from solid tumors in
vitro [7,15-17]. The mechanisms by which cancer cells
resist bortezomib are still largely unknown, although that
this resistance is thought to involve the activation of a
general stress response [7,15-17].
When exposed to environmental stress, cells rapidly
activate pathways generating a coordinated response
involving mRNA translation and turnover, that confers
protection against stress-induced damage and promotes
their survival. Noxious conditions (e.g. heat shock, oxida-
tive stress, UV radiations, viral infections, etc.) induce
cellular arrest of translation initiation [18]. This transla-
tional block is largely due to phosphorylation of transla-
tion initiation factor eIF2α [19]. Under normal growth
conditions, eIF2 associates with initiator Met-tRNAi
Met
(aminoacylated initiator methionyl-tRNA) and GTP, and
participates in the ribosomal selection of the start codon.
As a prelude to the joining of the small and large ribo-
somal subunits, GTP complexed with eIF2 is hydrolysed
to GDP, and eIF2-GDP is released from the translational
machinery. The GDP-bound eIF2 is recycled to the active
eIF2-GTP by a reaction catalyzed by the guanine nucle-
otide-exchange factor, eIF2B. Stress-induced phosphory-
lation of eIF2a at Ser51 changes this translation factor
from a substrate to an inhibitor of eIF2B. Since intracellu-
lar levels of eIF2B are approximately 10-20% of those of
eIF2 in the cytoplasm, phosphorylation of as little as 10%
of eIF2a can be sufficient to sequester virtually all the
available eIF2B, thereby blocking the nucleotide exchange
activity of eIF2B and therefore inhibiting protein synthe-
sis [20,21]. In metazoans, eIF2a is known to be specifi-
cally phosphorylated at Ser51 by at least four kinases that
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monitor stress response [18], namely PKR, which is
mainly activated by viral infection; protein kinase recep-
tor-like endoplasmic reticulum kinase (PERK), which is
activated during endoplasmic reticulum stress; GCN2, a
protein monitoring amino acid levels in cells and
responding to amino acid deprivation and proteasome
inhibition; and heme-regulated inhibitor kinase (HRI),
which senses osmotic stress, heat shock and oxidative
stress produced by arsenite. Stress-induced phosphoryla-
tion of eIF2α inhibits translation initiation by stalling
translation initiation complexes in an inactive form. The
accumulation of such stalled complexes is believed to
promote the formation of stress granules [22-24].
Stress granules (SGs) are cytoplasmic ribonucleopro-
tein-containing bodies whose formation is favored by
various stress conditions leading to eIF2α phosphoryla-
tion. These include UV irradiation [25], hypoxia [26],
arsenite [27-29], and viral infections [30,31]. Since these
stress agents are known to inhibit translation initiation, it
has been speculated that SGs might represent sites where
translation of specific mRNAs is repressed [24]. SGs
could repress translation in part by disrupting the inter-
action of mRNAs with translating ribosomes. A potential
role of SGs in translation repression is supported by the
observation that specific mRNAs are inefficiently
repressed when RNA-binding proteins that contribute to
SGs formation are altered [25,28,32-34]. SGs also contain
small ribosomal subunits, translation initiation factors
and signaling molecules [23,35]. Consistent with the pro-
posed role of SGs as temporary storage or triage sites for
untranslated mRNAs, large ribosomal subunits are
absent from these foci [27]. Once the inducing stress is
relieved, SGs gradually disassemble, which allows transla-
tion to resume, a condition essential for cell survival. It is
thus postulated that the formation of SGs is central to the
stress response by contributing to the reprogramming of
gene expression which is essential for cell survival [23]. It
is however only during the last few years that the patho-
logical importance of SGs formation in cancer cell resis-
tance to apoptosis became apparent. Indeed, the
induction of SGs upon exposure to hypoxia [36], or oxi-
dative stress (e.g. arsenite) [37] leads to tumor cell resis-
tance to apoptosis. One underlying mechanism appears
to involve the sequestration and inactivation of pro-apop-
totic factors in SGs. The formation of SGs induced by
hypoxia in cancer cells has been shown to inhibit apopto-
sis mediated by the anticancer drug etoposide. This effect
was attributed to the sequestration of the signaling scaf-
fold protein RACK1 into SGs, thus leading to the sup-
pression of stress-responsive MAP kinase apoptotic
pathways [36]. Other mechanisms by which SGs antago-
nize apoptosis could involve their sequestration of
mRNAs encoding key anti-apoptotic factors, thus pre-
venting degradation of the latter [25]. Although SGs have
been shown to form following some types of radiother-
apy, whether the formation of SGs can be triggered by
chemotherapeutic agents such as bortezomib has not
been investigated.
We have previously shown that the formation of SGs in
response to the proteasome inhibitor MG132 involves
phosphorylation of eIF2α at Ser51 [33]. We found that
mouse embryonic fibroblast (MEFs) eIF2αS51A, in which
eIF2α Ser51 has been mutated to Ala, fail to form SGs
upon MG132 treatment. We had also implicated the
GCN2 kinase phosphorylating eIF2α in the formation of
those SGs. W e reported that GCN2-/- MEFs cells have
decreased phosphorylation of eIF2α and fail to assemble
SGs following MG132 treatment. In the study herein, we
now show that bortezomib efficiently induces the forma-
tion of SGs in cancer cells. This response involves the
phosphorylation of eIF2α by HRI, as shown by the inhibi-
tion of bortezomib-induced SGs upon HRI depletion,
which also promotes apoptosis. This is the first study
describing the induction of SGs by a chemotherapeutic
compound. We speculate that the activation of HRI and
the resulting formation of SGs might constitute a mecha-
nism by which cancer cells resist bortezomib-mediated
apoptosis.
Results
Bortezomib induces the formation of SGs in cancer cells
We first assessed whether proteasome inhibition by bort-
ezomib could induce the formation of SGs. Indeed, borte-
zomib (1 μM, 3 h) efficiently induced SGs in HeLa cells,
as assessed by immunofluorescence using various SG
markers, namely fragile × mental retardation protein
(FMRP), RasGAP-associated endoribonuclease (G3BP),
the RNA-binding protein HuR, eIF4E, and fragile × men-
tal retardation syndrome-related protein 1 (FXR1) (Fig.
1A and 1E). Similar results were obtained using other
cancer cells such as Calu-I (lung cancer) and Caco (colon
cancer) cells (see below and data not shown). In contrast,
Hs578T breast cancer cells failed to form SGs in response
to bortezomib (see below). Thus, the formation of SGs
upon bortezomib treatment is not restricted to HeLa cells
and does not occur in all cancer cells. As expected, the
formation of SGs in HeLa cells correlated with a reduc-
tion of global translation as measured by metabolic label-
ing (Fig. 1B) and an induction of eIF2α phosphorylation
(Fig. 1C, top panel). Bortezomib-induced SGs are revers-
ible since they disassemble following prolonged treat-
ment with bortezomib (1 μM, 10 h) (Fig. 1D-E), allowing
a partial recovery of global translation (Fig. 1B). Intrigu-
ingly, the disassembly of SGs and the associated transla-
tion recovery do not require dephosphorylation of eIF2α
since phosphorylation of this factor remained high after
prolonged bortezomib addition (Fig. 1C, top  panel).
Moreover, this disassembly of SGs was not a consequenceFournier et al. Cancer Cell International 2010, 10:12
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of apoptosis, as assessed by the lack of activation of cas-
pase-3, the main effector of caspase-dependent apoptosis
(Fig. 1C, bottom  panel), and negative results in the
annexin V staining assay (Fig. 1F). The latter results indi-
cate that HeLa cells are resistant to bortezomib-mediated
apoptosis. Overall, our results show that bortezomib
induces the formation of SGs.
Depletion of HRI prevents bortezomib-induced SGs
We have previously implicated the GCN2 kinase as being
responsible for eIF2α phosphorylation in the formation of
SGs following MG132 treatment [33]. More recently, it
was shown that HRI-/- MEFs cells exhibit altered phos-
phorylation of eIF2α in response to both MG132 and
bortezomib [38]. Whether HRI, GCN2, or both are
responsible for bortezomib-mediated eIF2α phosphory-
lation, thus leading to the formation of SGs has not been
investigated in cancer cells. To address this question, we
first assessed the formation of SGs upon depletion of HRI
and GCN2. HeLa cells were treated with specific siRNAs
directed against HRI (HRI-1), GCN2 (GCN2-1), or with a
control siRNA. Due to the absence of suitable anti-HRI
antibodies, we assessed the ability of HRI-1 to knock
down its target mRNA using real-time quantitative
Figure 1 Bortezomib induces SGs formation. (A) HeLa cells were treated with 1 μM bortezomib for 3 h, fixed, permeabilized, and processed for 
immunofluorescence using antibodies against different SG markers. DAPI is used as a marker for nuclei. Pictures were taken using a 100× objective. 
(B) HeLa cells were treated with 1 μM bortezomib for the indicated times, then incubated with [35S] methionine (50 μCi/ml) for another 30 min. Pro-
teins were resolved on a SDS-polyacrylamide gel, stained with Coomassie Blue (bottom panel), and detected by autoradiography (top panel). (C) HeLa 
cells were treated with 1 μM bortezomib for the indicated times, and the level of phospho-eIF2α was analyzed by Western blotting using antibodies 
specific to the phosphorylated form (top panel). Detection of total eIF2α levels is shown in the middle panel and serves as a loading control. The acti-
vation of caspase-3 was analyzed using anti-caspase-3 antibodies (bottom panel). (D) HeLa cells were treated with 1 μM bortezomib for 10 h, fixed, 
permeabilized, and processed for immunofluorescence using antibodies against different SG markers. (E) The indicated histograms represent the per-
centage of cells harboring SGs (≥5 granules per cell) and is representative of the analysis of five different fields in three independent experiments for 
a total of 1000 cells. (F) Untreated HeLa cells or cells treated with bortezomib for 24 h were collected, stained with annexin V-FITC and PI, and analyzed 
by flow cytometry. The percentage of total dead or dying cells (indicated at the top of each panel) was defined as the sum of early (lower right box) 
and late (upper right box) apoptosis and is presented as the mean ± SEM from 2 independent experiments.Fournier et al. Cancer Cell International 2010, 10:12
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reverse transcription (qRT)-PCR analysis. The results
show that HRI-1 efficiently targeted HRI mRNA to deg-
radation (Fig. 2A). GCN2-1 also efficiently depleted
GCN2 mRNA as evidenced by (qRT)-PCR (Fig. 2B). The
induction of SGs by bortezomid was then assessed by
immunofluorescence using specific SGs markers (Fig.
2C). Less than 1% of cells treated with HRI siRNA dis-
played SGs in response to bortezomib. In contrast, more
than 40% of GCN2-1-treated cells formed SGs upon
bortezomib treatment. Control siRNA had a marginal
effect on SGs formation since > 60% of the cells thus
treated formed SGs following bortezomib treatment.
These results indicate that HRI depletion prevents the
induction of SGs by bortezomib. This effect of HRI deple-
tion is likely due to altered eIF2α phosphorylation as it
significantly reduced the extent of eIF2α phosphorylation
induced by bortezomib (Fig. 2D). However, the phospho-
rylation of eIF2α was not completely abolished in HRI-
depleted cells following bortezomib treatment. This indi-
cates that other kinases might contribute to the phospho-
rylation of eIF2α induced by bortezomib, as shown by the
slight reduction of that endpoint upon depletion of the
GCN2 kinase (Fig. 2D). Our results indicate that under
our conditions HRI is the major kinase involved in the
phosphorylation of eIF2α induced by bortezomib, with
GCN2 also contributing to this modification. This mini-
mal contribution of GCN2 could explain the residual
eIF2α phosphorylation observed in HRI-depleted cells.
Figure 2 Reducing HRI levels by siRNA prevents bortezomib-induced SGs formation. (A, C) HeLa cells were transfected for 48 h with anti-HRI 
(HRI-1) or anti-GCN2 siRNAs (GCN2-1), or with a control siRNA. (A, B) q(RT)-PCR of HRI (A) and GCN-2 mRNAs (B). Transfected cells were collected and 
their mRNA content was isolated. The amount of HRI and GCN-2 mRNAs relative to GAPDH mRNA was quantified by real-time q(RT)-PCR using the 
ΔΔCt method. The results are presented as the mean of triplicate measurements, with error bars corresponding to the SEM. (C) Transfected cells were 
processed for immunofluorescence using antibodies against different SG markers, as above. (D) HeLa cells were transfected for 48 h with HRI-1, GCN2-
1, or with a control siRNA, and then treated with bortezomib for 4 h. Cells were collected and protein extracts were analyzed by Western blot analysis 
for the amount of phospho- and total eIF2α as described in Figure 1. (E) HeLa cells were transfected for 48 h with HRI-1 siRNA or with control siRNA, 
and then treated with bortezomib for 3 h before a 30-min incubation with [35S] methionine (50 μCi/ml). Proteins were resolved on SDS-polyacrylamide 
gels, stained with Coomassie Blue (bottom panel), and detected by autoradiography (top panel).Fournier et al. Cancer Cell International 2010, 10:12
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Residual phosphorylation of eIF2α in HRI-/- is however
insufficient to trigger either the formation of SGs (Fig.
2C) or the inhibition of general translation (Fig. 2E). This
suggests that a threshold in the extent of eIF2α phospho-
rylation might be required to induce SGs upon treatment
with bortezomib. Thus, the phosphorylation of eIF2α
seems to be involved in the formation of SGs which is
induced by bortezomib. Our data clearly show that this
process requires the activity of HRI.
HRI depletion promotes apoptosis following bortezomib 
treatment
Previous studies have reported that MEFs lacking HRI fail
to form SGs following treatment with arsenite [39]. Quite
significantly, HRI deficiency resulted in cell death during
the recovery phase from arsenite treatment. Whether
HRI can promote resistance of cancer cells to chemother-
apeutic agents has not been investigated. We next
addressed the hypothesis that HRI depletion might sensi-
tize HeLa cells to bortezomib-mediated apoptosis. To
that purpose, HeLa cells treated with either HRI-1 or
control siRNAs were exposed to bortezomib for 10 and
24 h, and apoptosis was then assessed by assaying cas-
pase-3 activation and annexin V staining. Depletion of
HRI, which was confirmed by (qRT)-PCR, did not induce
significant apoptosis per se (Fig. 3A-B). However, HRI
depletion induced apoptosis in a high percentage of cells
upon bortezomib treatment (Fig. 3A, B).
To further confirm the role of HRI in promoting resis-
tance of cancer cells to bortezomib-induced apoptosis,
we performed clonogenic survival assays. For this, HeLa
cells were treated with anti-HRI or control siRNAs, incu-
bated with bortezomib and replated in fresh medium for
10 d, at which point colonies were counted. Depleting
HRI significantly decreased cell survival and growth fol-
lowing treatment with bortezomib (Fig. 3C). Overall, the
results identified HRI as an SGs-promoting factor that
confers resistance to bortezomib-induced apoptosis.
Since SGs are known to antagonize apoptosis [24], our
results suggest that HRI may promote cancer cell resis-
tance to bortezomib, at least in part, by inducing SGs.
One corollary of the latter finding is that cells which fail
to form SGs following bortezomib treatment might
become more susceptible to apoptosis. We assessed this
hypothesis using Hs578T cells, which do not form SGs
upon bortezomib treatment (Fig. 4A). HeLa and Calu-I
cells were used as positive controls. As shown using cas-
pase-3 activation and annexin V staining assays, borte-
zomib induces a high percentage of apoptosis in Hs578T
cells while both HeLa and Calu-I cells are resistant to that
treatment (Fig. 4B-C). As expected, bortezomib-medi-
ated apoptosis inhibited Hs578T cell growth after remov-
ing the drug, as evidenced by a clonogenic survival assay
(Fig. 4D). We obtained similar results using MDA-MB-
231 human breast carcinoma cells which do not form SGs
upon bortezomib treatment (data not shown). Thus, for
the set of cell lines selected here, the formation of SGs in
cancer cells correlates with their resistance to borte-
zomib.
Discussion
The present study shows for the first time that borte-
zomib can induce the reversible formation of SGs in can-
cer cells. The formation of SGs is associated with a
reduction of general mRNA translation, while their disas-
sembly following extended incubation with bortezomib
correlates with a partial recovery of general translation.
SGs production also correlates with the phosphorylation
of eIF2α by HRI. Depletion of HRI blocks both the forma-
tion of SGs and the chemoresistance of cancer cells to
bortezomib. Our studies unveil a specific survival path-
way that involves HRI and the formation of SGs, which
m i g h t  b e  t a r g e t e d  t o  p r e v e n t  c a n c e r  c e l l  r e s i s t a n c e  t o
bortezomib-mediated apoptosis.
It is well known that under different stress conditions,
eIF2α phosphorylation triggers SGs formation [23]. Our
present work demonstrates that depletion of HRI pre-
vents the formation of SGs and decreases eIF2α phospho-
rylation induced upon bortezomib treatment. However,
although HRI depletion completely prevents the forma-
tion of SGs induced by bortezomib, it leaves a residual
but significant amount of eIF2α phosphorylation unaf-
fected in that model. That residual level of eIF2α phos-
phorylation could be due either to an incomplete
suppression of HRI protein synthesis, or to the activation
of the GCN2 kinase, although we cannot exclude the pos-
sible contribution of the other eIF2α kinases [23]. Not-
withstanding these observations, the residual
phosphorylation of eIF2α observed in HRI-depleted cells
treated with bortezomib is clearly insufficient for trigger-
ing the formation of SGs. One possibility is that initiating
the formation of SGs requires a minimum threshold of
eIF2α phosphorylation. Another possibility is that, in the
bortezomib model, HRI might promote the formation of
SGs via mechanisms other than or in addition to eIF2α
phosphorylation. We and others have described the inac-
tivation of the translation initiation factor eIF4A as an
alternative pathway for the induction of SGs which
occurs independently of eIF2α phosphorylation and in
absence of any additional stress [30,40]. We subsequently
found that inactivation of other translation initiation fac-
tors also induces the formation of SGs in absence of stress
[41]. In this context, it is tempting to speculate that HRI
may affect other, as yet unknown translation initiation
factors in addition to phosphorylating eIF2α, thus trig-
gering the formation of SGs upon bortezomib treatment.
Other pathways whose inactivation impairs the induction
of SGs by stress agents also include microtubule polymer-Fournier et al. Cancer Cell International 2010, 10:12
http://www.cancerci.com/content/10/1/12
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ization and the acetylglucosamination (O-GlcNAc) modi-
fication of ribosomal proteins [24]. It will be interesting to
investigate the role of these pathways in the formation of
SGs and test if HRI depletion could affect those pathways
in cells treated with bortezomib.
Previous studies have shown that HRI-deficient MEFs
fail to form SGs upon arsenite treatment [39]. This effect
of HRI knockout is physiologically relevant since it
resulted in massive cell death during the recovery phase
from arsenite treatment [39]. However, this model was
not investigated in cancer cells, and more importantly,
the role of HRI activation in chemoresistance to borte-
zomib had never been addressed. Our work has thus
unveiled a critical role of HRI in promoting cancer cell
resistance to bortezomib, at least in part via the induction
of SGs. HRI is known to be highly expressed in erythroid
cells, although minimal expression of HRI is also found in
a wide range of non-erythroid cells [42,43]. It is thus
intriguing that HRI plays a critical role in promoting
resistance of non-erythroid cells such as HeLa to apopto-
sis. One possibility is that the expression and/or activa-
tion of HRI might be altered in cancer cells of non-
erythroid origin. Our q(RT)-PCR analysis indicates that
HRI mRNA is indeed abundant in HeLa cells and its high
expression remains unaltered by bortezomib treatment
(data not shown). It will be interesting to compare the
expression of HRI in bortezomib-resistant and -sensitive
cancer cells. The mechanism of HRI activation by borte-
Figure 3 Reducing HRI levels by siRNA promotes bortezomib-mediated apoptosis. (A) HeLa cells were transfected for 48 h with HRI-1 or control 
siRNA, treated with bortezomib for 24 h, and total extracted proteins were analyzed by Western blot using anti-caspase-3 antibodies (top panel). CP: 
cleaved product. FMRP serves as a loading control (bottom panel). (B) Following treatment with HRI-1 or control siRNA, HeLa cells were incubated with 
bortezomib for 24 h, then stained with annexin V-FITC and PI, and analyzed by flow cytometry. The percentage of total dead or dying cells (indicated 
at the top of each panel) was defined as the sum of early (lower right box) and late (upper right box) apoptosis and is presented as the mean ± SEM 
from two independent experiments. (C) Following treatment with HRI-1 or control siRNA, HeLa cells were incubated with bortezomib for 24 h, 
trypsinized, counted, replated in the absence of drug, and incubated for 10 d. Before colony counting, cells were fixed and dried. Populations > 50 
cells were counted as one surviving colony. Data were calculated as the percentage of surviving colonies relative to control (untreated) plates. The 
results are expressed as the mean of triplicate measurements.Fournier et al. Cancer Cell International 2010, 10:12
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zomib is currently unknown but may involve an interac-
tion with heat shock proteins. Hsp70 and Hsp90 are two
heat shock proteins which act as molecular chaperones to
modify the conformation of other proteins [44]. In reticu-
locytes, Hsp70 and Hsp90 were shown to activate HRI
following arsenite treatment [45]. In addition to their role
of chaperones, overexpression of Hsp70 and Hsp90 in
cancer cells confers protection against apoptosis. How-
ever, depletion of the inducible form of Hsp70 (Hsp72)
does not impair the induction of SGs by bortezomib (data
not shown), indicating that this protein may not be
involved in the activation of HRI under our conditions.
The role of Hsp90 in promoting bortezomib-induced HRI
activation, and the formation of SGs remains to be inves-
tigated.
How could the formation of SGs promote cancer cell
resistance to bortezomib-mediated apoptosis? SGs could
enhance this survival pathway by sequestering untrans-
lated mRNAs to free the ribosomes needed for the effi-
cient and rapid translation of mRNAs encoding anti-
apoptotic factors [22]. In addition, SGs might promote
tumor cell survival by preventing the degradation of
mRNAs encoding key survival proteins, as reported by
Moeller et al. [25]. In the latter study, it was shown that
radiotherapy induces the formation of SGs where
mRNAs encoding anti-apoptotic cytokines such as VEGF
are recruited and accumulated. Following reoxygenation,
however, SGs disassemble, thus releasing those mRNAs
that are then translated in large amounts. The ensuing
overproduction of cytokines then causes radioresistance
Figure 4 The formation of SGs correlates with resistance to bortezomib-mediated apoptosis. HeLa, Calu-1, and Hs578T cells were treated with 
bortezomib for 3 h (A) or 24 h (B to D). (A) Cells were processed for immunofluorescence to detect SGs using anti-FMRP and anti-G3BP antibodies. (B) 
Cells were stained with annexin V-FITC and PI, and analyzed by flow cytometry. The percentage of total dead or dying cells (indicated at the top of 
each panel) was defined as the sum of early (lower right box) and late (upper right box) apoptosis and is presented as the means ± SEM from two 
independent experiments. (C) Cells were harvested and protein extracts analyzed by Western blot for the activation of caspase-3 using anti-caspase-
3 antibodies. G3BP serves as a loading control. (D) Following bortezomib treatment for 24 h, cells were trypsinized, replated in the absence of drug, 
and incubated for 10 d. Before colony counting, cells were fixed and dried. Populations > 50 cells were counted as one surviving colony. Data were 
calculated as the percentage of surviving colonies relative to untreated plates. The results are presented as the mean of triplicate measurements.Fournier et al. Cancer Cell International 2010, 10:12
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of the tumor and its subsequent regrowth. This mecha-
nism could also explain the effects of depleting two SGs-
promoting factors, TIA and HDAC6, in preventing cell
survival. In these studies, depletion of either TIA or
HDAC6 was shown to prevent arsenite-induced SGs for-
mation, thus promoting apoptosis during recovery from
arsenite treatment [37,39]. Other mechanisms by which
SGs prevent cancer cell resistance to bortezomib might
involve the sequestration and inactivation of key apop-
totic signaling molecules such as RACK1 or TRAF2
[36,46], thus preventing the initiation of apoptotic cas-
cades. Clearly, further studies are needed to determine if
the formation of SGs is a key pathway leading to
chemoresistance to bortezomib.
Conclusions
The present study has established HRI as a critical factor
promoting chemoresistance in vitro. Consideration
should be taken about developing compounds to target
HRI, which could be combined with bortezomib to treat
chemoresistant cancers. We also provide a framework for
further documenting the therapeutic relevance of target-
ing the formation of SGs as a new tool to chemosensitize
cancer cells.
Methods
Cell lines and culture
HeLa, Calu-1 (lung cancer), and Hs 578T (breast cancer)
cells were obtained from the American Type Culture Col-
lection (Manassas, VA). Cells were cultured in DMEM
s u p p l e m e n t e d  w i t h  1 0 %  f e t a l  b o v i n e  s e r u m ,  p e n i c i l l i n ,
and streptomycin. All supplements for cell culture were
from Sigma-Aldrich (St. Louis, MO).
Drugs and drug treatments
Bortezomib was purchased from LC Laboratories and
dissolved in DMSO to a 65 mM stock solution, and stored
at -20°C. Bortezomib treatment was performed when
cells had reached 60-80% confluence.
[35S]Methionine labeling
Cells in 6-well plates were labeled for 30 min with 1 ml
methionine-free DMEM (Sigma) supplemented with 10%
fetal bovine serum and 50 μCi/ml of [35S] methionine
(Easy Tag, PerkinElmer/NEN Radiochemicals).
Antibodies
Anti-caspase-3, phospho-specific anti-eIF2α and the pan
anti-eIF2 antibodies were purchased from Cell Signaling
Technology (Beverly, MA). Anti-HuR, anti-G3BP, anti-
FMRP, anti-FXR1, and anti-eIF4E have been previously
described [30,33,41].
siRNA transfections
All siRNAs were purchased from Dharmacon. siRNA
transfections were performed in HeLa cells essentially as
previously documented [47] using Hiperfect reagent
according to the manufacturer's protocol (Qiagen and
Dharmacon). Twenty-four hours before transfections,
cells were trypsinized and plated to obtain 60-80% con-
fluence the day after. For a 6-well plate, annealed
duplexes were used at a final concentration of 50 nM.
Forty eight hours post-transfection, cells were either fixed
and processed for immunofluorescence or harvested for
protein and mRNA extraction.
Fluorescence microscopy
Immunofluorescence experiments were performed as
previously described [29]. Briefly, following fixation and
permeabilization, cells were incubated with primary anti-
bodies diluted in 0.1% Tween-20 in phosphate-buffered
saline (PBS) for 1 h at room temperature. After washing,
cells were incubated with goat anti-mouse/rabbit IgG
(H+L) secondary antibodies coupled to Alexa Fluor 488/
594. Fluorescence was visualized using an Olympus fluo-
rescence microscope equipped with AxioCam HR digital
camera and the the Axiovision acquisition software.
Images were compiled using Adobe Photoshop (Adobe
Systems, Mountain View, CA).
Real-time quantitative RT-PCR
RT-PCR reactions were performed using the Quantitect
Reverse Transcription kit (Qiagen). Each reaction was
performed by mixing 2 μl of RNA at 500 ng/μl, 10 μl of
RNase-free water, 2 μl of gDNA Wipeout Buffer 7×, 4 μl
of Quantiscript RT Buffer 5×, 1 μl of RT Primer Mix and
1 μl of Quantiscript Reverse Transcriptase.
Real-time PCR reactions were carried out using the
Power SYBR Green PCR Master mix (Applied Biosys-
tems) in a total volume of 25 μl: 12.5 μl of PCR Master
Mix, 0.67 μl of forward primer at 3.75 μM, 0.67 μl of
reverse primer at 3.75 μM, 9.2 μl of deionized water and 2
μl of RT-PCR. Reactions were run and data analyzed on
the MX3000 QRT PCR system (Applied Biosystems) with
a 4-stage program: first stage: 2-min incubation at 50°C;
second stage: 10-min incubation at 95°C, followed by a 2-
step reaction in the third stage: 95°C × 15 s and 55°C × 60
s for 40 cycles; and a fourth stage made of a 3-step reac-
tion (95°C × 15 s, 60°C × 20 s and 95°C × 15 s).
For preparing templates for the HRI mRNA, the oligo-
nucleotide pairs used were: 5'-GCCCTGATCAGCCA-
AGTAAAA-3' (forward primer), and 5'-TCTGGACGAG
TATGTGTTGGTG-3' (reverse primer). For preparing
templates for the GCN2 mRNA, the oligonucleotide pairs
used were: 5'-CAAGGCCTAACTGGTGAAGA-3' (for-
ward primer), and 5'-AGGTAGGTGGGCATTTAACC-3'
(reverse primer). For preparing templates for the glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) mRNA,
the oligonucleotide pairs used were: 5'-ACGACCA-
CTTTGTCAAGCTC-3' (forward primer), and 5'-GTTG
CTGTAGCCAAATTCGT-3' (reverse primer).Fournier et al. Cancer Cell International 2010, 10:12
http://www.cancerci.com/content/10/1/12
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Annexin V-fluorescein isothiocyanate/propidium iodide 
assay
Following treatments, both adherent and detached cells
were harvested. Cells were washed with ice-cold PBS,
then pelleted again at 1500 rpm for 10 min at 4°C, and
resuspended in ice-cold binding buffer (10 mM HEPES/
NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). The cells
were subsequently stained with annexin V-fluorescein
isothiocyanate (FITC) and propidium iodide (PI) for 15
min in the dark. A total of 50,000 cells were counted, and
dead cells were analyzed by flow cytometry.
Clonogenic survival assay and annexin V analysis
Cells were plated in duplicate and incubated for 24 h. Fol-
lowing treatments, cells were washed with PBS,
trypsinized, counted, replated (1 × 103 cells per well in 6-
well plates) in the absence of drug, and incubated for 10
d. Before colony counting, cells were washed with PBS,
stained with 0.1% (w/v) crystal violet in PBS containing
0.0037% (v/v) formaldehyde, rinsed with deionized water
and dried. Populations > 50 cells were counted as one sur-
viving colony.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors read and approved the final manuscript. MJF and CG have equally
contributed to this work.
Acknowledgements
We are grateful to Drs. Yves Labelle and Richard Poulin for providing helpful 
discussions and for editing the manuscript. This work was supported by a grant 
from the Canadian Institutes of Health Research (MOP-IC093226), an infrastruc-
ture grant from the Canada Foundation for Innovation (MOP-GF091050) and a 
start-up fund from the Centre Hospitalier Universitaire de Québec-Centre de 
recherche de l'hôpital St-François d'Assise (CHUQ-CRSFA) to RM. RM is the 
recipient of a Junior 1 Scholarship from the Fonds de Recherche en Santé du 
Québec (FRSQ).
Author Details
1Centre de recherche de l'hôpital St-François d'Assise (CHUQ/CRSFA), 10 rue de 
l'Espinay, Quebec, QC G1L 3L5, Canada and 2Département de biologie 
médicale, Université Laval, Quebec, Canada
References
1. Adams J: The development of proteasome inhibitors as anticancer 
drugs.  Cancer Cell 2004, 5(5):417-421.
2. Adams J: The proteasome: a suitable antineoplastic target.  Nat Rev 
Cancer 2004, 4(5):349-360.
3. Drexler HC: Activation of the cell death program by inhibition of 
proteasome function.  Proceedings of the National Academy of Sciences of 
the United States of America 1997, 94(3):855-860.
4. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H: 
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis 
in human monoblast U937 cells.  Biochem Biophys Res Commun 1995, 
217(3):1070-1077.
5. Lopes UG, Erhardt P, Yao R, Cooper GM: p53-dependent induction of 
apoptosis by proteasome inhibitors.  The Journal of biological chemistry 
1997, 272(20):12893-12896.
6. Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, 
Cusack JC Jr: Proteasome inhibition activates epidermal growth factor 
receptor (EGFR) and EGFR-independent mitogenic kinase signaling 
pathways in pancreatic cancer cells.  Clin Cancer Res 2008, 
14(16):5116-5123.
7. McConkey DJ, Zhu K: Mechanisms of proteasome inhibitor action and 
resistance in cancer.  Drug Resist Updat 2008, 11(4-5):164-179.
8. Richardson PG: A review of the proteasome inhibitor bortezomib in 
multiple myeloma.  Expert opinion on pharmacotherapy 2004, 
5(6):1321-1331.
9. Richardson PG, Anderson KC: Bortezomib: a novel therapy approved for 
multiple myeloma.  Clin Adv Hematol Oncol 2003, 1(10):596-600.
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, 
Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al.: A phase 2 study of 
bortezomib in relapsed, refractory myeloma.  The New England journal 
of medicine 2003, 348(26):2609-2617.
11. Richardson PG, Hideshima T, Anderson KC: Bortezomib (PS-341): a novel, 
first-in-class proteasome inhibitor for the treatment of multiple 
myeloma and other cancers.  Cancer Control 2003, 10(5):361-369.
12. Richardson PG, Hideshima T, Mitsiades C, Anderson K: Proteasome 
inhibition in hematologic malignancies.  Annals of medicine 2004, 
36(4):304-314.
13. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, 
Munshi N, Anderson KC: Bortezomib in the front-line treatment of 
multiple myeloma.  Expert Rev Anticancer Ther 2008, 8(7):1053-1072.
14. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, 
Terpos E, Sezer O: The potential of proteasome inhibitors in cancer 
therapy.  Expert opinion on investigational drugs 2008, 17(6):879-895.
15. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, 
Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, et al.: Differential cellular 
and molecular effects of bortezomib, a proteasome inhibitor, in human 
breast cancer cells.  Molecular cancer therapeutics 2006, 5(3):665-675.
16. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome 
inhibition as a novel therapeutic target in human cancer.  J Clin Oncol 
2005, 23(3):630-639.
17. Tang ZY, Wu YL, Gao SL, Shen HW: Effects of the proteasome inhibitor 
bortezomib on gene expression profiles of pancreatic cancer cells.  The 
Journal of surgical research 2008, 145(1):111-123.
18. Wek RC, Jiang HY, Anthony TG: Coping with stress: eIF2 kinases and 
translational control.  Biochem Soc Trans 2006, 34(Pt 1):7-11.
19. Holcik M, Sonenberg N: Translational control in stress and apoptosis.  
Nature reviews 2005, 6(4):318-327.
20. Barber GN: The dsRNA-dependent protein kinase, PKR and cell death.  
Cell death and differentiation 2005, 12(6):563-570.
21. Lu L, Han AP, Chen JJ: Translation initiation control by heme-regulated 
eukaryotic initiation factor 2alpha kinase in erythroid cells under 
cytoplasmic stresses.  Molecular and cellular biology 2001, 
21(23):7971-7980.
22. Anderson P, Kedersha N: Visibly stressed: the role of eIF2, TIA-1, and 
stress granules in protein translation.  Cell Stress Chaperones 2002, 
7(2):213-221.
23. Anderson P, Kedersha N: Stress granules: the Tao of RNA triage.  Trends in 
biochemical sciences 2008, 33(3):141-150.
24. Buchan JR, Parker R: Eukaryotic stress granules: the ins and outs of 
translation.  Molecular cell 2009, 36(6):932-941.
25. Moeller BJ, Cao Y, Li CY, Dewhirst MW: Radiation activates HIF-1 to 
regulate vascular radiosensitivity in tumors: role of reoxygenation, free 
radicals, and stress granules.  Cancer Cell 2004, 5(5):429-441.
26. Gardner LB: Hypoxic inhibition of nonsense-mediated RNA decay 
regulates gene expression and the integrated stress response.  
Molecular and cellular biology 2008, 28(11):3729-3741.
27. Kedersha N, Chen S, Gilks N, Li W, Miller IJ, Stahl J, Anderson P: Evidence 
that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation 
complexes are core constituents of mammalian stress granules.  
Molecular biology of the cell 2002, 13(1):195-210.
28. Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N, Golan DE, 
Anderson P: Dynamic shuttling of TIA-1 accompanies the recruitment 
of mRNA to mammalian stress granules.  J Cell Biol 2000, 
151(6):1257-1268.
29. Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW: 
Trapping of messenger RNA by Fragile × Mental Retardation protein 
Received: 9 March 2010 Accepted: 29 April 2010 
Published: 29 April 2010
This article is available from: http://www.cancerci.com/content/10/1/12 © 2010 Fournier et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cancer Cell International 2010, 10:12Fournier et al. Cancer Cell International 2010, 10:12
http://www.cancerci.com/content/10/1/12
Page 10 of 10
into cytoplasmic granules induces translation repression.  Human 
molecular genetics 2002, 11(24):3007-3017.
30. Mazroui R, Sukarieh R, Bordeleau ME, Kaufman RJ, Northcote P, Tanaka J, 
Gallouzi I, Pelletier J: Inhibition of ribosome recruitment induces stress 
granule formation independently of eukaryotic initiation factor 2alpha 
phosphorylation.  Molecular biology of the cell 2006, 17(10):4212-4219.
31. McInerney GM, Kedersha NL, Kaufman RJ, Anderson P, Liljestrom P: 
Importance of eIF2alpha phosphorylation and stress granule assembly 
in alphavirus translation regulation.  Molecular biology of the cell 2005, 
16(8):3753-3763.
32. Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, Dember LM, 
Anderson P: Stress granule assembly is mediated by prion-like 
aggregation of TIA-1.  Molecular biology of the cell 2004, 
15(12):5383-5398.
33. Mazroui R, Di Marco S, Kaufman RJ, Gallouzi IE: Inhibition of the 
ubiquitin-proteasome system induces stress granule formation.  
Molecular biology of the cell 2007, 18(7):2603-2618.
34. Tsai NP, Ho PC, Wei LN: Regulation of stress granule dynamics by Grb7 
and FAK signalling pathway.  The EMBO journal 2008, 27(5):715-726.
35. Anderson P, Kedersha N: RNA granules.  J Cell Biol 2006, 172(6):803-808.
36. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M: Formation of 
stress granules inhibits apoptosis by suppressing stress-responsive 
MAPK pathways.  Nature cell biology 2008.
37. Kwon S, Zhang Y, Matthias P: The deacetylase HDAC6 is a novel critical 
component of stress granules involved in the stress response.  Genes & 
development 2007, 21(24):3381-3394.
38. Yerlikaya A, Kimball SR, Stanley BA: Phosphorylation of eIF2alpha in 
response to 26S proteasome inhibition is mediated by the haem-
regulated inhibitor (HRI) kinase.  The Biochemical journal 2008, 
412(3):579-588.
39. McEwen E, Kedersha N, Song B, Scheuner D, Gilks N, Han A, Chen JJ, 
Anderson P, Kaufman RJ: Heme-regulated inhibitor kinase-mediated 
phosphorylation of eukaryotic translation initiation factor 2 inhibits 
translation, induces stress granule formation, and mediates survival 
upon arsenite exposure.  The Journal of biological chemistry 2005, 
280(17):16925-16933.
40. Dang Y, Kedersha N, Low WK, Romo D, Gorospe M, Kaufman R, Anderson 
P, Liu JO: Eukaryotic initiation factor 2alpha-independent pathway of 
stress granule induction by the natural product pateamine A.  The 
Journal of biological chemistry 2006, 281(43):32870-32878.
41. Mokas S, Mills JR, Garreau C, Fournier MJ, Robert F, Arya P, Kaufman RJ, 
Pelletier J, Mazroui R: Uncoupling stress granule assembly and 
translation initiation inhibition.  Molecular biology of the cell 2009, 
20(11):2673-2683.
42. Berlanga JJ, Herrero S, de Haro C: Characterization of the hemin-
sensitive eukaryotic initiation factor 2alpha kinase from mouse 
nonerythroid cells.  The Journal of biological chemistry 1998, 
273(48):32340-32346.
43. Mellor H, Flowers KM, Kimball SR, Jefferson LS: Cloning and 
characterization of cDNA encoding rat hemin-sensitive initiation 
factor-2 alpha (eIF-2 alpha) kinase. Evidence for multitissue expression.  
The Journal of biological chemistry 1994, 269(14):10201-10204.
44. Jolly C, Morimoto RI: Role of the heat shock response and molecular 
chaperones in oncogenesis and cell death.  Journal of the National 
Cancer Institute 2000, 92(19):1564-1572.
45. Lu L, Han AP, Chen JJ: Translation initiation control by heme-regulated 
eukaryotic initiation factor 2alpha kinase in erythroid cells under 
cytoplasmic stresses.  Molecular and cellular biology 2001, 
21(23):7971-7980.
46. Kim WJ, Back SH, Kim V, Ryu I, Jang SK: Sequestration of TRAF2 into stress 
granules interrupts tumor necrosis factor signaling under stress 
conditions.  Molecular and cellular biology 2005, 25(6):2450-2462.
47. Mazroui R, Di Marco S, Clair E, von Roretz C, Tenenbaum SA, Keene JD, 
Saleh M, Gallouzi IE: Caspase-mediated cleavage of HuR in the 
cytoplasm contributes to pp32/PHAP-I regulation of apoptosis.  J Cell 
Biol 2008, 180(1):113-127.
doi: 10.1186/1475-2867-10-12
Cite this article as: Fournier et al., The chemotherapeutic agent bortezomib 
induces the formation of stress granules Cancer Cell International 2010, 10:12